Prelude Capital Management’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Prelude Capital Management’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,501	Closed	-$1K	–	1788
2022 Q3	$1K	Hold	13,501	–	–	﹤0.01%	1507
2022 Q2	$1K	Hold	13,501	–	–	﹤0.01%	1772
2022 Q1	$3K	Sell	13,501 -5,000	-27%	-$1.5K	﹤0.01%	1722
2021 Q4	$10K	Buy	18,501 +400	+2%	+$227	﹤0.01%	1901
2021 Q3	$11K	Buy	18,101 +400	+2%	+$269	﹤0.01%	1628
2021 Q2	$13K	Buy	+17,701	New	+$10.8K	﹤0.01%	1574

Other funds holding IBER.WS

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Prelude Capital Management's IBER.WS Position: Q4 2022 in Review

Prelude Capital Management sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q4 2022, closing a stake of 13,501 shares — an estimated $1K sold.

Prelude Capital Management first reported a position in IBER.WS in Q2 2021 and held it in 6 quarters. The position peaked at $13K in Q2 2021. 33 funds tracked by Wall St. Rank hold IBER.WS as of Q4 2022.

Prelude Capital Management reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q4 2022 after selling out during the quarter.
Prelude Capital Management sold 13,501 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q4 2022, an estimated $1K.
Prelude Capital Management first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 6 quarters.
Prelude Capital Management's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $13K in Q2 2021.
33 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.